Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroquinidine versus placebo in high-risk Brugada syndrome patients with an implantable defibrillator
2008-000994-39Phase 3Active
- Sponsor
- CHU de Nantes
- Start
- Apr 2008
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of hydroquinidine in Brugada syndrome (2 arms), sponsored by CHU de Nantes. Primary endpoint: Time to appropriate implantable defibrillator shock. Started Apr 2008; status: active.
02
Drugs
hydroquinidine
03
Conditions
Brugada syndrome
Beyond the preview
Go deeper on 2008-000994-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000994-39.